Gilead’s First-In-Class Drug For Aggressive Breast Cancer On Track For EU Approval
Conditional Approval In Store For Janssen’s Non-Small Cell Lung Cancer Treatment
EU reviewers have recommended five new medicines and a pneumococcal vaccine for EU-wide approval. New uses of several approved medicines have also drawn the thumbs up, while the sponsor of a cancer drug has withdrawn its product from the review process.
